ABOUT
ZYMEDYNE IS A CALGARY-BASED BIOPHARMACEUTICAL COMPANY THAT AIMS TO DEVELOP NON-OPIOID TREATMENTS FOR CHRONIC, NEUROPATHIC PAIN.
Founded by pain researchers Dr. Gerald Zamponi and Dr. Chris Bladen, their technology is based on targeting specific proteins called “T-type” calcium channels that are known to be crucial in pain signalling, and are involved in other neurological and genetic diseases.
Chronic pain is one of the most serious health challenges that faces society today and current therapies are not universally effective and often have detrimental adverse effects, such as weight gain (Gabapentinoids), respiratory depression and addiction (the opioid crisis). As a result, many patients are left with unmanaged chronic pain and new approaches are sorely needed.
Zymedyne holds the IP on a newly discovered molecular mechanism that causes increased T-Type calcium channel expression and elevated pain signals. This non-opioid dependent mechanism provides an exciting avenue for finding drugs that can regulate pain without the detrimental side effects of opioids. We are currently developing and refining small organic compounds that target this mechanism. Our aim is to continue developing these and other ion channel targeting compounds, with the ultimate goal of providing safer, non opioid-based pain-relieving alternatives to chronic pain sufferers.
OUR VISION
Zymedyne aims to develop safer, more effective treatments for chronic, neuropathic pain by targeting human Cav3.2 “T-type” calcium channels that are known to be crucial in pain signalling. Unlike opioids, our technology aims to achieve pain relief without the detrimental side effects of weight gain, respiratory depression and addiction that plague current users of opioid-based medications.
Our mission
Chronic pain is a debilitating condition that affects up to 30% of adult Canadians and is one of the most serious health challenges that faces society today. Current therapies are not universally effective and often have detrimental adverse effects, such as weight gain (e.g., Gabapentinoids), respiratory depression (opioids) and addiction (opioid crisis). As a result, many patients are left with unmanaged chronic pain and new approaches are sorely needed. Zymedyne have the IP on a newly discovered molecular mechanism that causes T-Type calcium channel (protein)expression to be increased and thus pain signals to be elevated. This non-opioid dependent mechanism provides an exciting avenue for finding drugs that can regulate pain without the detrimental side effects of opioids. We currently have several drugs that target this mechanism and have shown potent analgesia (pain relief) in animal models of pain. We will be further developing these compounds with a view to patenting and licensing to Pharmaceutical companies. We also aim to partner with larger Pharma companies to do R+D for them on their ion channel targeting compounds and to jointly develop non opioid-based pain-relieving pharmaceuticals.
In short, our mission is to develop next generation Non-opioid based Analgesics to improve Patient Quality of life.